---
document_datetime: 2025-02-25 14:17:28
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trumenba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: trumenba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.4185552
conversion_datetime: 2025-12-24 20:45:40.801747
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Trumenba

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                            |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------|
| II/0053              | Update of sections 4.4 and 5.1 of the SmPC in order to amend an existing warning on immunocompromised individuals and to add immunogenicity data in individuals 10 years of age and above with complement deficiencies or splenic dysfunction based on final results from study | 16/01/2025                          |                                             | SmPC                             | Please refer to Scientific Discussion 'Trumenba-H-C-4051- II-0053' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | B1971060; listed as a category 3 study in the RMP. This was an open-label, single-arm, multicentre trial in which up to 50 immunocompromised participants â‰¥10 years of age with asplenia (anatomic or functional) or complement deficiency have been enrolled and received Trumenba on a 2-dose, 0- and 6-month schedule. The RMP version 8.0 has been approved. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                  |            |            |      |                                                                          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------|
| II/0052   | Update of sections 4.2 and 4.8 of the SmPC in order to add information regarding fever in infants 2 months of age based on final results from study C3511002; this is a Phase 2b trial to assess the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age. In addition, the MAH is taking this opportunity to implement minor editorial updates to SmPC section 4.4, in line with the QRD product information template version 10.4. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/07/2024 | 06/09/2024 | SmPC | Please refer to Scientific Discussion \"Trumenba EMEA/H/C/004051/II/0052\" |
| II/0050/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/04/2024 | n/a        |      |                                                                          |

<div style=\"page-break-after: always\"></div>

|           | Replacement/addition of a site where batch control/testing takes place B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                                                                               |            |            |                 | arrangements   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------|
| IAIN/0051 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/10/2023 | 06/09/2024 | Annex II and PL | responsible    |
| IB/0049/G | This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation | 22/06/2023 | n/a        |                 |                |

<div style=\"page-break-after: always\"></div>

| IB/0048/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                             | 25/05/2023   | n/a   |           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IB/0046     | B.II.z - Quality change - Finished product - Other                                                                                                                                                                                                                                                                                                                                                                             | 06/04/2023   | n/a   | variation |
| IB/0045/G   | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 06/04/2023   | n/a   |           |
| II/0042     | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                         | 09/02/2023   | n/a   |           |

<div style=\"page-break-after: always\"></div>

| IB/0043             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation   | 23/11/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0044             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                    | 09/11/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0037             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                               | 22/09/2022   | 04/10/2023 | SmPC        | Please refer to Scientific Discussion Trumenba/H/C/004051/II/0037                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0041             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                      | 09/08/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0040             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | 10/06/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10607 /202110 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                             | 10/06/2022   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0036              | Renewal of the marketing authorisation.                                                                                                         | 24/02/2022   | 25/04/2022 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Trumenba in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Trumenba is removed from the additional monitoring list. Therefore, the statement that this medicinal product is subject to additional monitoring is removed from the |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                   |            |            |             | summary of product characteristics and the package leaflet.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------|
| IB/0039             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                      | 06/04/2022 | n/a        |             |                                                               |
| N/0035              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                  | 24/09/2021 | 25/04/2022 | PL          |                                                               |
| PSUSA/10607 /202010 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                               | 10/06/2021 | n/a        |             | PRAC Recommendation - maintenance                             |
| II/0032             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                 | 06/05/2021 | 25/04/2022 | SmPC and PL |                                                               |
| N/0033              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                  | 27/11/2020 | 25/04/2022 | PL          |                                                               |
| PSUSA/10607 /202004 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                               | 26/11/2020 | n/a        |             | PRAC Recommendation - maintenance                             |
| II/0027/G           | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 01/10/2020 | n/a        |             |                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0030/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 11/09/2020 | n/a |
| IB/0029/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/07/2020 | n/a |

<div style=\"page-break-after: always\"></div>

|           | A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------|
| IB/0028/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of | 06/07/2020 | n/a        |                                  |                                                                |
| II/0013   | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on the results from two paediatric studies: B1971017 and B1971035. The MAH took the opportunity to carry out typographical and linguistic improvements throughout the PI. The Package Leaflet is updated in accordance. The RMP version 2.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to submit a corrected version of the final report of study B1971016, which                                                                     | 28/05/2020 | 05/11/2020 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion Trumenba-H-C-4051- II-13 |

<div style=\"page-break-after: always\"></div>

|                     | application. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10607 /201910 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/05/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                 |
| II/0023             | Update of sections 4.8 and 5.1 of the SmPC in order to update the safety and immunogenicity information based on final results from study B1971033 listed as a category 3 study in the RMP (MEA007); this is a duration of immunity study to assess persistence of hSBA response for up to 48 months after completion of vaccination with Trumenba and the immunogenicity, safety, and tolerability of a booster dose of Trumenba. The RMP version 3.0 has also been submitted, including changes related to this variation, changes agreed during another ongoing variation (II-13) and editorial changes. In addition, the Marketing authorisation holder (MAH) took the opportunity to include editorial changes in Annex II, in the labelling and in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/05/2020 | 05/11/2020 | SmPC, Annex II, Labelling and PL | The results of a phase 3 study (B1971033) confirmed the duration of immunity and persistence of hSBA response for up to 48 months after completion of vaccination with Trumenba. The MAH has updated the information contained about persistence of immune and booster responses in Tables 6 and 7. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0026   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 29/04/2020   | n/a        |          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|
| IB/0025   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/03/2020   | n/a        |          |
| II/0020/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - | 06/02/2020   | 05/11/2020 | Annex II |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other   |            |            |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10607 /201904 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/11/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0022             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/11/2019 | 05/11/2020 | Annex II and PL |                                   |
| IB/0021             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/11/2019 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10607 /201810   | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant,                                                                                                                                                                                                                                                                                                                                                  | 16/05/2019   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| II/0016/G             | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 16/05/2019   | n/a   |                                     |
| IB/0018               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                              | 18/02/2019   | n/a   |                                     |
| IB/0014/G             | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                | 07/01/2019   | n/a   |                                     |
| IB/0015               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                 | 17/12/2018   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10607 /201805 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                      | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0011             | Update of section 4.4 of the SmPC in order to add a warning about an increased risk of invasive disease caused by Neisseria meningitidis serogroup B in persons with complement deficiencies or using concomitant treatments inhibiting terminal complement activation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 08/11/2018 | 18/06/2020 | SmPC                   | The CHMP considered that the post marketing data provided by the MAH strongly suggest that after successful vaccination with a meningococcal vaccine, the risk of meningococcal disease is increased during the use of eculizumab. The product information has therefore ben updated to reflect that persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk of invasive disease caused by Neisseria meningitidis serogroup B, even if they develop antibodies following vaccination with |
| IB/0012             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                      | 16/10/2018 | 18/06/2020 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| T/0009              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                      | 11/07/2018 | 27/09/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0008             | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a                                                                                                                                                                                 | 05/07/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | biol. reference preparation not covered by an approved protocol                                                                                                                                                                                                                                                                                                                              |            |            |                            |                                                                                                                                                                                                                                                                                           |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10607 /201711 | Periodic Safety Update EU Single assessment - meningococcal group B vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                          | 14/06/2018 | n/a        |                            | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                         |
| IAIN/0007/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/04/2018 | 27/09/2018 | Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                           |
| IB/0006             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                | 09/04/2018 | n/a        |                            |                                                                                                                                                                                                                                                                                           |
| IB/0004             | B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                        | 15/02/2018 | n/a        |                            |                                                                                                                                                                                                                                                                                           |
| II/0002/G           | This was an application for a group of variations. Update of section 4.4 of the SmPC in order to add a warning on syncope based on review of post- marketing data. Update of section 4.8 of the SmPC in                                                                                                                                                                                      | 14/12/2017 | 27/09/2018 | SmPC and PL                | A cumulative review of cases of syncope occurring in association with administration of Trumenba showed that as with other injectable vaccines, syncope (fainting) can occur in association with administration of Trumenba. Procedures should be in place to avoid injury from fainting. |

<div style=\"page-break-after: always\"></div>

|         | order to update the safety information regarding booster vaccination based a review of adverse events data reported in the interim clinical study report (B1971033). The package leaflet is updated accordingly. In addition, the MAH took the opportunity to make a clarification on interchangeability of Trumenba in section 4.2 of the SmPC and to update the list of local representatives in the package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | The review of adverse events data reported in the interim clinical study report (B1971033) showed that adverse reactions following booster vaccination in 268 subjects aged 15 to 23 years were similar to adverse reactions during the primary Trumenba vaccination series approximately 4 years earlier. Additionally, the MAH took the opportunity to clarify that there are no data available on the interchangeability of Trumenba with other meningococcal group B vaccines to complete the vaccination series.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0003 | B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/11/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0001 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                             | 08/09/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |